14 March 2019
Sofitel Legend Amsterdam The Grand
2019 Presenting Companies
Aelin Therapeutics (BEL)
Aelin Therapeutics will exploit its proprietary Pept-in™ protein knockdown platform as a novel modality in drug development. The company is based on a very comprehensive preclinical package illustrating different applications of the technology (in bacteria, fungi, viruses, cancer cells). The technology is furthermore protected by a strong and growing IP portfolio.
Amarin Corporation (IRE)
Amarin is a rapidly growing pharmaceutical company focused on therapeutics to improve cardiovascular health. Vascepa® (
Artois Pharma (UK)
Arvelle Therapeutics (SWZ)
Atlantic Therapeutics (IRE)
Binx Health (UK)
Cardior Pharmaceuticals (GER)
Cardior is a privately held biopharmaceutical company founded by Prof. Thomas Thum out of the Hannover Medical School. The company is dedicated to becoming world-leader in design, research and development of non-coding RNA-based therapeutics for cardiovascular diseases. Cardior aims to market its products in collaboration with a strategic pharma-partner after clinical validation.
Eloxx Pharmaceuticals (ISR)
Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates that are designed to treat rare and ultra-rare premature stop codon diseases. Premature stop codons are point mutations that disrupt protein synthesis from messenger RNA. As a consequence, patients with premature stop codon diseases have short half-life messenger RNA that produce truncated, nonfunctional proteins, accounting for some of the most severe phenotypes in these genetic diseases. These premature stop codons have been identified in over 2,000 rare and ultra-rare diseases. Read-through therapeutic development is focused on extending mRNA half-life and enabling protein synthesis to continue through the premature stop codons to restore protein functionality. Eloxx’s lead product candidate, ELX-02, is a small molecule drug candidate designed to restore full-length functional proteins. ELX-02 is in the early stages of clinical development focusing on cystic fibrosis cystinosis. ELX-02 has not been approved by any global regulatory body. Eloxx is headquartered in Waltham, MA. with R&D operations in Rehovot, Israel.
eTheRNA is a clinical stage immunotherapy company developing mRNA based therapeutic products for the treatment of cancer and infectious disease. To date it has completed 4 clinical studies and has 3 studies underway currently. The company has built a new GMP facility which also provides contract manufacturing services.
Evotec AG (GER)
Evotec is a drug discovery company focused on rapidly progressing innovative product approaches with its customers. It operates worldwide providing the highest quality stand-alone and integrated drug discovery solutions, covering all activities from target identification to IND-enabling studies and high-end CMC (Chemistry, manufacturing and controls). The Company focuses on key therapeutic areas including neuronal diseases, diabetes and diabetic complications, oncology, pain, anti-infectives, respiratory and fibrosis.
For additional information please go to www.evotec.com.
Galapagos (Euronext & NASDAQ: GLPG) is a clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines with novel modes of action. Galapagos’ pipeline comprises Phase 3 through to discovery programs in cystic fibrosis, inflammation, fibrosis, osteoarthritis and other indications. Our target discovery platform has delivered three novel mechanisms showing promising patient results in, respectively, inflammatory diseases, idiopathic fibrosis and atopic dermatitis. Galapagos is focused on the development and commercialization of novel medicines that will improve people’s lives. The Galapagos group, including fee-for-service subsidiary Fidelta, has approximately 578 employees, operating from its Mechelen, Belgium headquarters and facilities in the Netherlands, France, and Croatia. More information at www.glpg.com.
GTX medical (NL)
ImCheck Therapeutics is a Marseille-based, privately-held biotech company developing nenext-generationmmuno-modulatory antibodies acting on both adaptive and innate immunity for the treatment of cancer and other immune related diseases.
With a “precision medicine-based” translational approach and several established academic collaborations, ImCheck is uniquely positioned to develop the right therapy for each patient.
Immunic AG (GER)
Kiadis Pharma (NL)
Kiadis allodepleted T-cell immunotherapy product can make haploidentical hematopoietic stem cell transplantations safer and more effective. Phase 2 data with lead product ATIR given after HSCT in blood cancer patients shows a clinically relevant improvement over literature for the Baltimore protocol, without risk of severe chronic Graft versus Host Disease.
Merus is a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics with the goal of treating and potentially curing cancer patients. Our most advanced development programs use the Biclonics® format. Biclonics® are capable of simultaneously attacking tumors in multiple ways. For example by activating the immune system to kill tumor cells and directly inhibiting tumor cell growth and survival pathways
OxThera AB (SWE)
OxThera is developing a novel treatment, Oxabact, for Primary hyperoxaluria (PH), a fatal ultra-orphan disease in children, and where there are currently no available therapies. The company has initiated a pivotal Phase III study in PH with Oxabact in order to stop and/or delay disease progression. Oxabact holds orphan drug designations in the EU and the US for the treatment of PH, and in the EU for treatment of Short Bowel Syndrome (SBS).
Probiodrug AG (GER)
Probiodrug AG is a publicly traded (Euronext Amsterdam, PBD) company dedicated to the research and development of new therapeutic products for the treatment of Alzheimer’s disease (“AD”). The company is backed by blue chip institutional investors and lead by an experienced management team with profound track-record in drug research and development, financing and business development.
Sequana Medical (CH)
Sequana Medical is a commercial stage medtech and an innovator in the management of liver disease, heart failure and other fluid imbalance disorders. Cirrhotic-ascites is a large market and forecast to grow significantly due to the increasing prevalence of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).
SNIPR Biome (DEN)
Vetex Medical (IRE)
Vivasure Medical (IRE)
Percutaneous large (12F+) arteriotomy closure is an area of unmet clinical need which is growing rapidly, driven by the increased penetration of procedures such as Transcatheter Aortic Valve Repair. Vivasure’s technology enables a fully percutaneous approach for these patients, yielding significant clinical and economic benefits for patients, physicians and payers.
uniQure is delivering on the promise of gene therapy, single treatments with potentially curative results. We have developed a modular technology platform to rapidly bring new disease-modifying therapies to patients with severe genetic diseases.
We are advancing a focused pipeline of innovative gene therapies and have established clinical proof-of-concept in our lead indication, hemophilia B, and preclinical proof-of-concept in Huntington’s disease. Our pipeline of adeno-associated virus (AAV)-based gene therapies has been developed using an innovative technology platform, supported by industry-leading proprietary commercial-grade manufacturing capabilities.
Zealand Pharma (DEN)
Zealand Pharma A/S (Nasdaq: ZEAL) is a biotechnology company focused on the discovery, design and development of innovative peptide-based medicines. Zealand has a portfolio of medicines and product candidates under license collaborations with Sanofi and Boehringer Ingelheim and a pipeline of internal product candidates focusing on specialty gastrointestinal and metabolic diseases.